PTK2 and neoplasm: In a recent issue of the journal Nature Medicine, Jiang and colleagues identify that inhibition of the non-receptor tyrosine kinase, Focal Adhesion Kinase (FAK), can sensitise genetically engineered mouse (GEM) models of pancreatic cancer to the anti-tumour effects of immune checkpoint blockade [3].